One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • COMPOSITIONS AND METHODS FOR REDUCING FOOD CRAVINGS
    Publication number: 20140309252
    Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Inventors: Anthony A. McKinney, Gary Tollefson, Michael A. Cowley
  • Polymorphic Forms of Naltrexone
    Publication number: 20140303200
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: April 10, 2014
    Publication date: October 9, 2014
    Applicant: Alkermes, Inc.
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Peripheral opioid receptor antagonists and uses thereof
    Patent number: 8853232
    Abstract: The present invention provides a compound of formula I: wherein R1, R2, R2? and X? are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 7, 2014
    Assignees: Wyeth LLC, Progenics Pharmaceuticals., Inc.
    Inventors: Alfred A. Avey, Appavu Chandrasekaren, Harold D. Doshan, Julio Perez, Yakov Rotshteyn
  • Abuse-Resistant Formulations
    Publication number: 20140294953
    Abstract: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.
    Type: Application
    Filed: June 5, 2014
    Publication date: October 2, 2014
    Inventors: Ehab Hamed, Manuel A. Vega Zepeda
  • PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE
    Publication number: 20140296277
    Abstract: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Bianca Brögmann, Silke Mühlau, Christof Spitzley
  • TAMPER RESISTANT IMMEDIATE RELEASE FORMULATIONS
    Publication number: 20140294947
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising a gelling agent; (ii) an optional barrier layer encompassing the core; (iii) an active layer comprising a drug susceptible to abuse encompassing the core or barrier layer; and (iv) an optional controlled release excipient; wherein the dosage form provides an immediate or controlled release; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration.
    Type: Application
    Filed: September 14, 2012
    Publication date: October 2, 2014
    Inventor: Kevin Reilly
  • SEQUESTERED ANTAGONIST FORMULATIONS
    Publication number: 20140296276
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 2, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Christopher Breder, Benjamin Oshlack, Curtis Wright
  • Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
    Publication number: 20140296274
    Abstract: This invention relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists and dextro enantiomers thereof for the treatment of pain, where the opioid antagonists treat pain by blocking TLR4. More preferably, the dextro opioid/TLR4 antagonist enantiomer treats pain by blocking TLR4 while not affecting the opioid receptors and therefore avoiding adverse effects associated with blocking the opioid receptors. Examples of opioid antagonist and their dextro enantiomers include naltrexone, naloxone and nalmefene, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
    Type: Application
    Filed: March 27, 2013
    Publication date: October 2, 2014
    Inventor: Annette Channa Toledano
  • GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140294956
    Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 2, 2014
    Inventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
  • MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
    Publication number: 20140294955
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Applicants: PALADIN LABS INC., PALADIN LABS EUROPE LIMITED, PALADIN LABS (BARBADOS) INC.
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain
    Publication number: 20140296275
    Abstract: Disclosed are compositions for treatment of pain comprising, a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor (TLR4) and the second compound is an alpha-2-delta ligand that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone, naloxone and nalmefene. Examples of an alpha-2-delta ligand include gabapentin and pregabalin, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic pain.
    Type: Application
    Filed: March 27, 2013
    Publication date: October 2, 2014
    Inventor: Annette Channa Toledano
  • 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives
    Patent number: 8846709
    Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
  • Matrix for sustained, invariant and independent release of active compounds
    Patent number: 8846091
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Euro-Celtique S.A.
    Inventors: Bianca Brögmann, Silke Mühlah, Christof Spitzley
  • Pharmaceutical compositions for the deterrence and/or prevention of abuse
    Patent number: 8846104
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: September 30, 2014
    Assignee: Alpharma Pharmaceuticals LLC
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • Matrix for sustained, invariant and independent release of active compounds
    Patent number: 8846090
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: September 30, 2014
    Assignee: Euro-Celtique S.A.
    Inventors: Bianca Brögmann, Silke Muhlau, Christof Spitzley
  • Method for ameliorating pruritus
    Patent number: 8846039
    Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: September 30, 2014
    Assignee: Asan Laboratories Company (Cayman), Limited
    Inventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
  • Extended Release Compositions Comprising Hydrocodone And Acetaminophen For Rapid Onset And Prolonged Analgesia That May Be Administered Without Regard To Food
    Publication number: 20140288113
    Abstract: The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
    Type: Application
    Filed: February 24, 2014
    Publication date: September 25, 2014
    Applicant: MALLINCKRODT LLC
    Inventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
  • BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR
    Publication number: 20140286931
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Chengzhi Zhang
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20140288112
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 15, 2014
    Publication date: September 25, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • Tamper-resistant pharmaceutical compositions of opioids and other drugs
    Patent number: 8840928
    Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: September 23, 2014
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
  • Clay Composites and their Applications
    Publication number: 20140276484
    Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Materials Modification Inc
    Inventors: Kausik Mukhopadhyay, Krishnaswamy Kasthuri Rangan, Tirumalai Srinivas Sudarshan
  • Combinations of Opioid/TLR4 Antagonists and Acetyl-Para-Aminophenol (APAP) for Use in the Treatment of Pain
    Publication number: 20140275141
    Abstract: Disclosed are compositions for the treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is acetyl-para-aminophenol (APAP) that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic and nociceptive pain.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventor: Annette Channa Toledano
  • ABUSE-DETERRENT DOSAGE FORMS
    Publication number: 20140271848
    Abstract: Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventors: Debora L. Guido, Haiyong Huang
  • Compositions with a Rheological Modifier to Reduce Dissolution Variability
    Publication number: 20140275147
    Abstract: The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Su Il Yum, Wendy Chao, Huey-Ching Su, Roger Fu, Michael S. Zamloot, Karl Bratin, Ravi M. Shanker
  • MORPHINE FORMULATIONS
    Publication number: 20140275144
    Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Becton Dickinson France S.A.S.
    Inventors: Alain CUINE, Didier Hoarau, Pauline Romain
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
    Publication number: 20140271898
    Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
    Publication number: 20140275145
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
  • TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS
    Publication number: 20140271896
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Rama ABU SHMEIS, Sheetal Muley, Zhixin Zong
  • Combinations of Opioid/TLR4 Antagonist and a Cyclooxygenase (COX) Inhibitor for Use in the Treatment of Pain
    Publication number: 20140275142
    Abstract: Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is a cyclooxygenase (COX) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone. Examples of cyclooxygenase inhibitors include ibuprofen, naproxen, meloxicam, diclofenac and meclofenamic acid, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic pain and nociceptive pain with an allodynic component.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventor: Annette Channa Toledano
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
    Publication number: 20140275038
    Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
    Publication number: 20140271788
    Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: MONOSOL RX, LLC
    Inventor: MonoSol Rx, LLC
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
    Publication number: 20140275039
    Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
    Publication number: 20140275149
    Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food
    Publication number: 20140275143
    Abstract: The present disclosure provides pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state. The present disclosure further provides pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides reduced abuse potential.
    Type: Application
    Filed: February 24, 2014
    Publication date: September 18, 2014
    Applicant: MALLINCKRODT LLC
    Inventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
  • ABUSE RESISTANT CAPSULE
    Publication number: 20140271835
    Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventor: Simone Wengner
  • CONTROLLED RELEASE HYDROCODONE FORMULATIONS
    Publication number: 20140271840
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Abuse Deterrent Solid Dosage Form for Immediate Release with Functional Score
    Publication number: 20140271849
    Abstract: The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Siva N. Raman, Jae Han Park, Sunil K. Battu, Eric A. Burge, David W. Bogan
  • SUSTAINED RELEASE FORMULATION OF NALBUPHINE
    Publication number: 20140271852
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Application
    Filed: May 29, 2014
    Publication date: September 18, 2014
    Applicant: PENWEST PHARMACEUTICALS CO.
    Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
  • SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
    Publication number: 20140271789
    Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 18, 2014
    Applicant: MonoSol Rx, LLC
    Inventors: Garry L. Myers, Eric Dadey
  • ORALLY ADMINISTRABLE, SELF-SUPPORTING DISSOLVING FILM DOSAGE FORMS
    Publication number: 20140275148
    Abstract: Orally administrable, self-supporting, dissolving film dosage forms comprising an active ingredient and a polyvinyl alcohol-polyethylene glycol graft copolymer, and methods of orally administering the film dosage forms are provided.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Novus Pharma LLC
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • MORPHINE SULFATE METHANOLIC SOLVATE, PROCESSES FOR MAKING SAME AND RELATED COMPOSITIONS AND METHODS FOR TREATING PAIN
    Publication number: 20140275146
    Abstract: Processes for reducing the amount of impurities, especially ?,?-unsaturated ketones (ABUK), in materials containing morphine. Novel compounds, namely low ABUK morphine sulfate methanolic solvate, and a novel crystal form are also described. The method for making morphine sulfate methanolic solvate comprises mixing a morphine free base composition with methanol to form a solution and adding a liquid comprising sulfuric acid to the solution to form a morphine sulfate methanolic solvate precipitate. A method of making a morphine sulfate compound comprises drying the morphine sulfate methanolic solvate in the presence of water vapor, such that methanol molecules are removed and replaced with water vapor molecules. A composition for treating pain comprises the morphine sulfate compound and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Johnson Matthey Public Limited Company
    Inventor: Robert S. Marmor
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE
    Publication number: 20140275150
    Abstract: Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. Shah, Ray J. DiFalco, Stefan Aigner
  • TAMPER RESISTANT DOSAGE FORM COMPRISING AN ADSORBENT AND AN ADVERSE AGENT
    Publication number: 20140256764
    Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 11, 2014
    Applicant: Purdue Pharma L.P.
    Inventor: Osvaldo Abreu
  • PAIN MEDICINE COMBINATION AND USES THEREOF
    Publication number: 20140256763
    Abstract: This application describes compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Mindlab LLC
    Inventors: Lawrence R. James, Laura A. James
  • 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN
    Publication number: 20140255308
    Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Gavril Pasternak, Susruta Majumdar
  • MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20140256717
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 11, 2014
    Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)
    Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
    Patent number: 8829020
    Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: September 9, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
  • Stable tablet containing 4,5-epoxymorphinan derivative
    Patent number: 8829019
    Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: September 9, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Kotoe Ohta, Suguru Takaki, Yasuhide Horiuchi
  • Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
    Patent number: 8828978
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: September 9, 2014
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20140249171
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: July 31, 2013
    Publication date: September 4, 2014
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen